Global Mucopolysaccharidosis Treatment Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

Mucopolysaccharidosis (MPS) treatment is the therapy of hereditary illnesses in which the body cannot break down glycosaminoglycan (long sugar chains) due to the lack or failure of certain enzymes. A deficiency or malfunction of a specific lysosomal enzyme commonly causes mucopolysaccharidosis.

Sizing and Forecast
The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.2 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%.  The  growth in the historic period can be attributed to enzyme replacement therapy (ert), improved diagnostic tools, advocacy and awareness, gene therapy development, healthcare infrastructure development.

The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%.  The growth in the forecast period can be attributed to advancements in gene editing, regulatory changes and support, patient access initiatives, emerging therapeutic modalities, precision medicine approaches. Major trends in the forecast period include caregiver support programs, focus on symptom management, education and training initiatives, expanded global access, advances in biomarker development.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report

Segmentation & Regional Insights
The mucopolysaccharidosis treatment market covered in this report is segmented –
1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy
2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases
3) By Route of Administration: Intravenous, Intracerebroventricular
4) By End-User: Hospitals, Specialty Clinics, Other End-Users

North America  was the largest region in the mucopolysaccharidosis treatment market in 2023. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East,  Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of various forms of mucopolysaccharidosis is expected to propel the growth of the mucopolysaccharidosis treatment market going forward. Mucopolysaccharide is a form of complex carbohydrate that accumulates in bodily tissues because the individual affected lacks the particular enzyme required to digest it. Mucopolysaccharidosis (MPS) therapy can help prevent disease development by lowering glycosaminoglycan (GAG) formation in the body, controlling symptoms, and preventing complications through various therapeutic approaches. For instance, in February 2021, according to a report shared by National Library of Medicine, a US-based medical library, there were 3.62 MPS I and MPS VI births for every 100,000 live births. MPS III represented 11% of all cases, with a calculated rate of 1.8 per 100,000 live births. Therefore, the increasing prevalence of various forms of mucopolysaccharidosis will drive the mucopolysaccharidosis treatment market.

Key Industry Players
Major companies operating in the mucopolysaccharidosis treatment market report are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Sarepta Therapeutics Inc., Esteve SA, JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Eidos Therapeutics Inc., Neurogene Inc., Immusoft Corporation, Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., Rimedion Inc., Eloxx Pharmaceuticals Inc., iBio Inc., Abeona Therapeutics Inc.

The mucopolysaccharidosis treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model